An interventional study of High-Intensity Laser Therapy (HILT) and Diaphragmatic Breathing Exercises in Tuberculosis, sponsored by RSUP Persahabatan. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by RSUP Persahabatan · Not applicable, Interventional, and Treatment
Pulmonary tuberculosis can result in impaired lung function and reduced functional capacity. This study evaluated the short-term effectiveness of High-Intensity Laser Therapy (HILT) combined with diaphragmatic breathing exercises in patients with drug-sensitive pulmonary tuberculosis during the continuation phase of treatment.
This single-blind, randomized, sham-controlled clinical trial included 36 participants assigned to an intervention group or a control group. The intervention group received one session of HILT combined with diaphragmatic breathing exercises, while the control group received sham laser treatment combined with the same breathing exercises.
Lung function and functional capacity were assessed using spirometry, peak expiratory flow, the six-minute walk test, and chest expansion measurements. Assessments were conducted at baseline and 24 hours after the intervention.
1,170 studies on the registry are indexed under Tuberculosis; 175 are open to participants now.
This study's enrollment of 36 is below the median of 150 across 820 interventional studies indexed under Tuberculosis.
Browse Tuberculosis studies →RSUP Persahabatan is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received one session of High-Intensity Laser Therapy (HILT) using a BTL-6000 device (1064 nm wavelength, 5 W power, and 50 J/cm² energy density), combined with diaphragmatic breathing exercises.
Device: High-Intensity Laser Therapy (HILT) · Behavioral: Diaphragmatic Breathing Exercises
Participants received sham laser treatment using the BTL-6000 device, which emitted LED light without therapeutic laser emission, combined with diaphragmatic breathing exercises.
Behavioral: Diaphragmatic Breathing Exercises · Device: Sham Laser
High-Intensity Laser Therapy was administered using a BTL-6000 High Intensity Laser device at a wavelength of 1064 nm, in biostimulation mode, with a power of 5 W and an energy density of 50 J/cm². A single treatment session was performed, involving scanning over the pulmonary regions based on radiological findings, as well as the diaphragm and upper trapezius muscles.
Participants performed diaphragmatic breathing exercises in the supine position, with one hand placed on the chest and the other on the abdomen. They were instructed to inhale slowly through the nose, emphasizing abdominal movement while minimizing chest movement. Each inhalation and exhalation lasted approximately six seconds, repeated for five cycles. The exercise was administered to both groups during the same treatment session.
Sham laser treatment was administered using the BTL-6000 High Intensity Laser device. The device was switched on but emitted LED light only, without therapeutic laser emission. The procedure was used as a sham comparator in the control group.
Change in Six-Minute Walk Test Distance
Time frame: Baseline to 24 hours post-intervention
Change in Forced Expiratory Volume in One Second (FEV1)
Time frame: Baseline to 24 hours
Change in Forced Vital Capacity (FVC)
Time frame: Baseline to 24 hours
Change in Peak Expiratory Flow (PEF)
Time frame: Baseline to 24 hours
Change in Chest Expansion
Time frame: Baseline to 24 hours
Plan to share: No — The investigators do not plan to make individual participant data (IPD) available to other researchers. This decision is based on participant confidentiality considerations and the provisions of the informed consent documents, which do not explicitly authorize external sharing of individual-level data. The study involves sensitive clinical information, and participant privacy will be maintained in accordance with the approved ethical requirements. Only aggregate research findings will be disseminated through scientific publications and presentations.
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
RSUP Persahabatan